Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank
NewsNEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company has entered…
Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
NewsNEW YORK--(BUSINESS WIRE)--Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the appointment…
Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
NewsNEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today…
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
NewsMarch 23, 2021 07:30 AM Eastern Daylight Time
NEW YORK & CHICAGO--(BUSINESS WIRE)--Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary Microdose…
EYENOVIA TO REPORT FOURTH QUARTER AND FULL YEAR 2020 RESULTS ON THURSDAY, MARCH 25
NewsNEW YORK, March 18, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today…
Eyenovia to Participate in the 33rd Annual Roth Conference
NewsNEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology,…
Eyenovia Announces FDA Acceptance of the MydCombi NDA
NewsMarch 02, 2021 07:30 AM Eastern Standard Time
NEW YORK--(BUSINESS WIRE)--Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced…
Eyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
NewsEyenovia to present at the Ophthalmology Innovation Summit (OIS) Presbyopia Innovation Showcase
NEW YORK--(BUSINESS WIRE)--Jan. 26, 2021-- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing…
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
News
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia
Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Topline Results Expected First Half of 2021 December 16, 2020…
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis
News
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually
December 29, 2020 07:00 AM Eastern Standard Time
NEW YORK--(BUSINESS WIRE)--Eyenovia,…